Metabolic & Cardiometabolic
statins does not decrease major cardiac events
In plain terms: Do statins only help if a coronary calcium or CT scan already shows plaque?
Part of: 💊 statins
Contradicted: while imaging cohorts show statin benefit concentrates where coronary calcium is present, primary-prevention RCTs (e.g. JUPITER) and the CTT individual-data meta-analysis show statins cut cardiovascular events even in unscanned, lower-risk people, and the proportional benefit is independent of baseline risk — so gating benefit on pre-existing/imaged coronary disease is not supported.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Contradicted by randomised evidence: the CTT individual-participant analysis across 27 trials found statins reducing major vascular events in participants with no history of vascular disease. The imaging cohorts behind the claim show benefit concentrating where coronary calcium is present, which is an argument about who benefits most, not about whether benefit exists.
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mitchell JD, Fergestrom N, Gage BF, Paisley R, Moon P, Novak E, Cheezum M, Shaw LJ, Villines TC 2018 · J Am Coll Cardiol | observational | supports | high | n=13,644; statin cut MACE with CAC (SHR 0.76) but NOT without CAC (SHR 1.00); interaction p<0.0001; NNT 100(CAC1-100) to 12(CAC>100) |
| Mihaylova, Emberson, Blackwell, Keech, Simes, Barnes, Voysey, Gray, Collins, Baigent 2012 · Lancet 380(9841):581-590 | meta-analysis | contradicts | high | CTT IPD MA (27 RCTs, 174 149). In participants with no history of vascular disease, MVE RR per 1.0 mmol/L LDL 0.61 (99% CI 0.45-0.81) and 0.66 (0.57-0.77) in the <5% and 5-<10% risk strata (stratum sizes in statin-vs-control trials 24 790 and 28 362, of whom 96% and 87% had no vascular history), 0.63/0.64 after excluding diabetes/CKD — benefit not confined to established disease. Stratified by modelled risk and history, not CAC/CTA. |
| Kambalapalli S, Bhandari M, Punnanithinont N, Iskander B, Khan MA, Budoff M 2025 · Curr Atheroscler Rep | observational | mixed | moderate | Review: CAC>100 or >=75th pct marks clearest statin benefit; statins also stabilize/reduce non-calcified plaque, so CAC=0 does not equal no drug effect |
| Kalra, Ray, Bajaj, Kushner, Wilcox, Dicklin, Kirkpatrick, Maki 2026 · J Clin Lipidol 2026;20(4):738-749 | meta-analysis | contradicts | high | Meta-analysis in participants WITHOUT established cardiovascular disease: 'In CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated with a 30% RRR in 4-point MACE' (RR 0.70; 95% CI 0.67-0.74; 14 trials, n = 98,537). That contradicts the claim's core assertion that statins reduce major cardiac events only in established/advanced coronary disease. It does NOT test the claim's parenthetical limb: no CAC or CTA stratification appears anywhere, so the zero/low-calcium subgroup question is untouched by this evidence. The paper also makes no primary-vs-secondary-prevention comparison of its own - that contrast is a Background statement about CTT analyses, not a finding here. Abstract-only read; heavy author industry COI. |
| Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group 2008 · N Engl J Med 2008 Nov 20;359(21):2195-2207 | RCT | contradicts | high | JUPITER: 17,802 apparently healthy adults with LDL <130 mg/dL and hs-CRP >=2.0 mg/L, i.e. no established coronary disease - primary composite 0.77 vs 1.36 events per 100 person-years (HR 0.56, 95% CI 0.46-0.69, P<0.00001), MI HR 0.46, stroke HR 0.52. Refutes 'benefit only in established/advanced CAD'. No coronary imaging was performed, so the 'minimal benefit when CAC/CTA zero' half of the claim is untested here. ↩ SUPERSEDED — pooled in the review above, counted once |
| Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M 2018 · JACC Cardiovasc Imaging | observational | supports | moderate | MESA n=5,600: among statin-eligible, CAC=0 (44%) had low event rate; 10yr NNT 87 at CAC=0 vs 19 at CAC>100 for ASCVD |
| Kritharides, Nicholls 2015 · Future Cardiol | meta-analysis | contradicts | high | COMMENTARY, no new data (PubMed PublicationType 'Comment'), restating Fulcher et al. 2015. Its baseline-risk finding does cut against the claim - 'Baseline risk substantially affected the absolute number of events prevented, but did not affect the proportional benefit attributed to the use of statins' - so the contradicts direction is right, but the vote belongs to the primary (PMID 25579834), which is not in the vault. Zero-weighted per CONVENTIONS 5. Caution for recompute: dropping a contradicts vote RAISES this claim's score from -0.66 toward the -0.60 band edge. |
| Kostapanos, Elisaf 2011 · World J Cardiol | RCT | contradicts | low | Narrative review, no original data. JUPITER 'was conducted in apparently healthy individuals with normal levels of low-density lipoprotein cholesterol (LDL-C < 130 mg/dL)' who 'would not have qualified for statin treatment according to current treatment guidelines', and the review concludes that 'statins may be effective drugs in the primary prevention of cardiovascular disease in normocholesterolemic individuals at moderate-to-high risk' — which contradicts the claim as worded. Caveat kept explicit: the review never stratifies benefit by coronary imaging or established coronary disease, so this is an indirect contradiction of an imaging-gated hypothesis, not a head-on test of it. |
| Charalambous M, Filler R, Soteriades ES, Abitria R, Kiser J, Fernandez-Montero A, Kales SN, Smith D 2026 · Cureus | observational | tested-null | low | Systematic review: CAC>0 carried 4-5x higher event risk; CAC=0 reliably predicts very low event rates, supporting risk-based statin allocation |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.